Author: digi

SOP for Wearables/Digital Biomarkers Acquisition and Validation

Posted on digi By digi

SOP for Wearables/Digital Biomarkers Acquisition and Validation { “@context”: “https://schema.org”, “@type”: “Article”, “mainEntityOfPage”: { “@type”: “WebPage”, “@id”: “https://www.clinicalstudies.in/sop-for-wearables-digital-biomarkers-acquisition-and-validation” }, “headline”: “SOP for Wearables/Digital Biomarkers Acquisition and Validation”, “description”: “This SOP outlines standardized procedures for acquisition, management, and validation of data from wearable devices and digital biomarkers in clinical trials. It ensures compliance with FDA, EMA,…

Read More “SOP for Wearables/Digital Biomarkers Acquisition and Validation” »

SOP for GCP, SOP for IDE/Device

Rare Oncology Clinical Trials Conducted in the UK

Posted on digi By digi

Rare Oncology Clinical Trials Conducted in the UK Conducting Rare Oncology Clinical Trials in the United Kingdom Rare oncology clinical trials represent one of the most complex and vital areas of clinical research in the United Kingdom (UK). These studies focus on cancers that affect small patient populations, such as sarcomas, glioblastomas, and paediatric malignancies….

Read More “Rare Oncology Clinical Trials Conducted in the UK” »

Clinical Trials in UK, Country-Specific Clinical Trials

Harmonization of Lab Ranges Across Regions with Risk-Based Oversight Strategies

Posted on digi By digi

Harmonization of Lab Ranges Across Regions with Risk-Based Oversight Strategies Standardizing Lab Reference Ranges in Global Clinical Trials: A Risk-Based Oversight Guide Introduction: The Problem with Regional Lab Range Variability In multinational clinical trials, inconsistencies in laboratory reference ranges across countries and regions can lead to protocol deviations, data interpretation issues, and regulatory scrutiny. Variations…

Read More “Harmonization of Lab Ranges Across Regions with Risk-Based Oversight Strategies” »

Central vs Local Labs, Laboratory and Sample Management

Adaptive Randomization Methods in Clinical Trials

Posted on digi By digi

Adaptive Randomization Methods in Clinical Trials Adaptive Randomization Strategies in Modern Clinical Trials Introduction: Why Adaptive Randomization Matters Traditional clinical trials use fixed randomization ratios (e.g., 1:1 allocation). However, adaptive randomization allows adjustment of allocation probabilities during a trial based on accumulating interim data. This design can assign more patients to promising treatments, improve efficiency,…

Read More “Adaptive Randomization Methods in Clinical Trials” »

Adaptive Modifications Based on Interim Data, Interim Analysis and Trial Termination

Phase 4 and Post-Marketing Commitments in the EU

Posted on digi By digi

Phase 4 and Post-Marketing Commitments in the EU Understanding Phase 4 and Post-Marketing Commitments in the EU Phase 4 clinical trials, also known as post-marketing studies, play a crucial role in ensuring that medicines remain safe and effective after regulatory approval. In the European Union (EU), these studies are governed by the EU Clinical Trial…

Read More “Phase 4 and Post-Marketing Commitments in the EU” »

Clinical Trials in EU, Country-Specific Clinical Trials

Local IRB/Ethics Committees in Chinese Clinical Trials

Posted on digi By digi

Local IRB/Ethics Committees in Chinese Clinical Trials Role of Local IRBs and Ethics Committees in Chinese Clinical Trials Introduction Institutional Review Boards (IRBs), also referred to as ethics committees, are essential to ensuring that clinical trials uphold ethical principles, safeguard patient rights, and comply with Good Clinical Practice (GCP). In China, the ethics review system…

Read More “Local IRB/Ethics Committees in Chinese Clinical Trials” »

Clinical Trials in China, Country-Specific Clinical Trials

Top CRO Market Leaders in Indian Clinical Research and Their Regulatory Performance

Posted on digi By digi

Top CRO Market Leaders in Indian Clinical Research and Their Regulatory Performance India’s Leading CROs and Their Role in Shaping Clinical Research Outsourcing Introduction India has emerged as a significant player in global clinical trial outsourcing, offering a unique combination of regulatory support, scientific expertise, and cost efficiency. As the industry matures, several Contract Research…

Read More “Top CRO Market Leaders in Indian Clinical Research and Their Regulatory Performance” »

Clinical Trials in India, Country-Specific Clinical Trials

Compliance Playbook – Data Integration from Multiple Lab Sources

Posted on digi By digi

Compliance Playbook – Data Integration from Multiple Lab Sources Regulatory Guide to Integrating Data from Multiple Laboratory Sources in Clinical Trials Introduction: The Complexity of Multi-Lab Data in Clinical Trials Clinical trials often involve multiple laboratory sources, such as central labs, local labs, and specialty laboratories. While this decentralized approach offers flexibility and regional accessibility,…

Read More “Compliance Playbook – Data Integration from Multiple Lab Sources” »

Central vs Local Labs, Laboratory and Sample Management

CRO Partnerships in Post-Brexit UK Clinical Research

Posted on digi By digi

CRO Partnerships in Post-Brexit UK Clinical Research How CRO Partnerships Drive Clinical Research in Post-Brexit UK Contract Research Organisations (CROs) have long been essential partners in the UK clinical research landscape, offering expertise in monitoring, data management, pharmacovigilance, and regulatory compliance. Following Brexit, the role of CROs has become even more significant as sponsors adapt…

Read More “CRO Partnerships in Post-Brexit UK Clinical Research” »

Clinical Trials in UK, Country-Specific Clinical Trials

Vendor Risk Categorization Frameworks

Posted on digi By digi

Vendor Risk Categorization Frameworks Building Effective Vendor Risk Categorization Frameworks for Clinical Trials Introduction: Why Vendor Risk Categorization Matters Clinical trials rely on multiple outsourced vendors—CROs, laboratories, IT providers, and logistics partners—each carrying unique risks. To comply with ICH-GCP E6(R2), FDA, and EMA requirements, sponsors must apply risk-based oversight. Vendor risk categorization frameworks provide structured…

Read More “Vendor Risk Categorization Frameworks” »

Due Diligence and Risk Assessment, Outsourcing and Vendor Management